key: cord-0687441-d3rpnyxa
authors: Duan, Chaorui; Buerer, Luke; Wang, Jing; Kaplan, Samuel; Sabalewski, Gavin; Jay, Gregory D.; Monaghan, Sean; Arena, Andrea E.; Fairbrother, William G.
title: Efficient detection of SARS-CoV-2 from exhaled breath.
date: 2021-09-29
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2021.09.005
sha: 0cbf9de4dc7c8bec9c131ff718e2b8a0d7a35a18
doc_id: 687441
cord_uid: d3rpnyxa

SARS-CoV-2 is transmitted through airborne particles in exhaled breath, causing severe respiratory disease. SARS-CoV-2 is typically collected by nasopharyngeal swab and detected by PCR; however, patients can test positive for 3 months after infection. Without the ability to assay SARS-CoV-2 in human breath, it is not possible to learn the transmission risk from infected individuals. To detect virus in breath, the Bubbler - a breathalyzer that reverse transcribes RNA from airborne SARS-CoV-2 particles into a sample-specific barcoded cDNA was developed. Tests of the Bubbler on 70 patients admitted to Rhode Island Hospital showed that it was both more predictive of lower respiratory track involvement (i.e. abnormal chest X-rays) and less invasive than alternatives. In addition, the Bubbler sample of exhaled air was 3 times more enriched for SARS-CoV-2 RNA than tongue swabs implying viral particles were being directly sampled. The demonstration of how barcode-enabled Bubblers can simultaneously diagnose large batches of pooled samples at a detection limit of 334 genomic copies/sample was given. Diagnosis by sequencing can provide additional information such as viral load and strain identity. Finally, the Bubbler was configured to sample nucleic acids in water droplets circulating in air, demonstrating this device’s potential for environmental monitoring and the protective effect of adequate ventilation.

SARS-CoV-2 is a coronavirus that gains entry into a wide range of cell types through the ACE2 receptor and causes COVID-19, a severe respiratory disorder.

COVID-19 is characterized by fever, a dry cough and a variety of other symptoms. While COVID-19 can present with symptoms outside the lower respiratory tract, a dangerous trajectory can cause inflammation in the lungs resulting in pneumonia. As SARS-CoV-2 is an airborne pathogen presumably the infection status of the lungs and airway is not only predictive of disease outcome but also risk of transmission.

Early research from different types of exhaled breath (e.g. sneezing, coughing and talking loudly) has demonstrated a wide range of droplet sizes that persist in the air 1 2 . In general, the smaller drops persist longer, and larger droplets reduce to smaller droplets through evaporation. Culturing droplets for the commensural Str. viridans illustrated how pathogens could travel within aerosolized droplets in exhaled breath. These studies concluded that 90% of airborne bacteria can J o u r n a l P r e -p r o o f persist in droplets for 30-60 min in unventilated space. Smaller viruses could presumably persist longer and travel further.

Testing strategies for active or prior infection rely on detection of viral RNA or antibodies to the virus. Collection is usually performed in the upper respiratory tract by saliva or nasopharyngeal (NP) swab, which have comparable sensitivities (97% agreement) 3 . While it has been demonstrated that these samples contain active virus, a recent study suggested influenza was compartmentalized 4 5 . Viral loads in the upper respiratory tract (nasal) were uncorrelated with symptoms of the lower respiratory tract (i.e. coughing), whereas viral loads in aerosolized particles was correlated with the severity of cough symptoms. As involvement of the lower respiratory is often a precursor to more severe COVID-19 outcomes, there is an argument for a more direct sampling approach that focuses on exhaled breath.

There are several devices designed to capture exhaled breath condensate.

Breathalyzers have been developed to sample metabolites. Prior studies failed to J o u r n a l P r e -p r o o f detect differences between lung microbiome and the microbiome of the upper respiratory tract 6 . However, there are cellular genes expressed predominantly in the lung such as the family of Surfactant-associated proteins (e.g. SP-A). ACE-2 expression is found, but not restricted to the lung 7 .

Here, the aim of this study is to improve SARS-CoV-2 detection by simplifying the assay and broadening the compartments tested. A clinical study to sample SARS-CoV-2 from three points in the respiratory tract was designed. Oral samples (saliva/tongue scrapes) and exhaled breath are compared to the traditional NP swab. To simplify the assay, the study explored the viability of performing reverse transcription (RT) directly on a sample without RNA extraction, eliminating the need to stabilize a sample and allowing the assay to be performed at home. The study describes the design and testing of a breathalyzer called the Bubbler that directly samples aerosolized particles in exhaled breath.

J o u r n a l P r e -p r o o f

Bubblers are constructed by first creating three openings in the cap of a 15mL

Falcon tube ( Figure 1B) . A glass Pasteur pipette, through which subjects can exhale into the tube, is fitted to the central opening while the two holes on either side act as escape vents for the exhaled air. 4 L of SuperScript TM IV reverse transcriptase (Thermo Fisher Scientific, Waltham, MA, catalog #18090050), 16 L of transcriptase reaction buffer, 4 L of 100 mM DTT, 4 L of RNaseOUT and 4 L of nuclease-free water are mixed with 4 L of pooled RT primers and 4 L of 10 mM dNTPs to make a 40 L RT reaction mixture for each Bubbler. The RT primer pool consists of 8 primers targeted to the SARS-CoV-2 N gene and one primer for the RNase P gene pooled to a concentration of 20 M ( Table 1 ). The bottom of the Falcon tube is filled with this RT reaction mixture, and then 100 L of cold mineral oil is added on top of the mixture. The bubbler is first tested on 18S rRNA ( Figure 2 ). J o u r n a l P r e -p r o o f

Study participants were screened in an Emergency Department in Providence, RI from May 2020 -January 2021 ( Figure 3 ). Patients were eligible if they were >18 years old, had COVID-19 testing collected or historically available within 72hrs, spoke English, and were able to understand and provide written informed consent. Patients unable to provide informed consent as determined by the clinical providers were excluded. From each enrolled subject, ~15 seconds of exhaled breath were collected in the Bubbler as well as 2 tongue scrapings. Each tongue scrape was then dipped in 20 L of the RT reaction mixture described above. After ~30 minutes at room temperature, samples were transferred to -80°C until laboratory testing.

Upon arrival at the laboratory, samples were heated to 55C to inactivate any remaining virus. 0.5 L of RT mixture was taken from each of the patient samples J o u r n a l P r e -p r o o f and mixed with 1 L of PCR primer mix, 5 L of Power SYBR™ Green PCR Master Mix (Thermo Fisher Scientific, catalog #4367659) and 3.5 L of nuclease-free water to make a 10 L reaction for real-time PCR analysis (see Table 1 (Table 2 ). McNemar's Test was used in all of the above dichotomized comparisons. Estimates were reported with 95% CI's.

Estimates were then rank ordered from least to most positive and tested using the Cochrane-Armitage test for trend (using one-tailed hypothesis testing) to determine if the rates of abnormal chest XR results are predicted by B-PCR.

In order to analyze the difference in relative SARS-CoV-2 expression between the L-PCR and B-PCR tests, a subset of the data was taken that contained only positive test results. Using the comparative Ct method, the Ct numbers for SARS-CoV-2 amplification were converted to their relative expression levels compared to the RNase P control in the sample. The median values of these relative expressions were calculated separately for both the tongue scrape and the Bubbler. Several successive t-tests were performed after excluding outliers in the data. For each test, the median relative expression of SARS-CoV-2 was significantly larger for the Bubbler than for the tongue scrape (Supplemental Table S1 ).

A DNA oligonucleotide of the SARS-CoV-2 N gene with a T7 promoter was synthesized at Integrated DNA Technologies (IDT, Coralville, IA). PCR amplification was performed on this oligonucleotide using Q5 High fidelity DNA J o u r n a l P r e -p r o o f polymerase (NEB Ipswich, MA) to prepare template for in vitro transcription (IVT).

Primers are listed in Table 3 . A single PCR amplicon was confirmed by agarose gel electrophoresis. IVT was performed using Riboprobe System-T7 kit (Promega, catalog# P1440) following the manufacturer's recommendations. The DNA template was removed by digestion with DNase I, and IVT RNA was subsequently extracted using phenol (pH4.7) : chloroform and precipitated by ethanol.

A five-fold serial dilution using the IVT N gene RNA was performed in triplicate.

To begin, 5 L of IVT N gene RNA is diluted with 20 L of human control total RNA. 5 L of this mixture is then transferred to another tube and an additional 20 L of human RNA is added. For each replicate, this process is repeated to obtain 10 dilutions of SARS-CoV-2 RNA, and 2 water-based blanks are used as controls.

Barcoded RT primers targeting the SARS-CoV-2 N gene and the human 18S rRNA gene were synthesized in a 96-well plate at IDT (Table 3) with RNase I and exonuclease I, respectively. After Proteinase K treatment, all the cDNA were pooled and purified using QIAquick PCR Purification kit (Qiagen, Hilden, Germany, catalog #28004), then in vitro transcription was performed using the T7 promoter. The resulting antisense RNA was reverse transcribed to cDNA via SuperScript IV transcriptase using specific RT primers both for 18S rRNA and N gene. The following two-step nested PCR amplification uses the common reverse primer and two different forward primers for each target ( Table   3 ). The samples were then pooled and amplicon sequencing was performed to quantify the representation of each dilution level's barcode.

The copy number of the IVT SARS-CoV-2 N gene RNA used to construct the serial dilution samples was quantified by real-time PCR. Briefly, RNA was reverse transcribed to cDNA via SuperScript IV transcriptase using random 9mer RT primers. The resulting cDNA was added to the qPCR reaction using Applied Biosystems Power SYBR™ Green PCR Master Mix. IVT N gene RNA were used to prepare absolute standards, then a standard curve was generated to calculate copy number. The real-time PCR reaction was performed on ViiA 7 Real Time PCR Systems using CDC N1 SARS-CoV-2 primers.

The common reverse primer (RP) sequence used in the serial dilutions described above was mapped to the reads obtained from amplicon sequencing using bowtie2 (v2.2.4). The sample barcode and UMI were obtained from the adjacent sequence for reads containing the full-length RP. These reads were then trimmed J o u r n a l P r e -p r o o f of non-target sequence (i.e. the UMI, sample barcode and RP) and mapped to the targeted sequence (either SARS-CoV-2 or 18S rRNA) to confirm that they contain the expected sequence between the forward primer (either FP1 or FP2) and the 1 st round reverse transcription primer ( Figure 4B ). Read counts for each dilution level's barcode were calculated from the set of reads that contained the expected RP and target sequence. As each dilution level should contain five-fold less SARS-CoV-2 RNA as the previous level, the expected read count for a given dilution level is set to one fifth the number of reads observed from the previous level. The expectation for the read counts of the two water-based blank samples was taken to be zero. The expected read count for the first dilution level was set to the observed read count for plotting purposes but this level was excluded from correlation calculations. The Pearson correlation coefficient was calculated for the following comparisons: observed FP1 counts vs. observed FP2 counts, observed FP1 counts vs. expected FP1 counts, and observed FP2 counts vs. Table 4 .

While SARS-CoV-2 is predominantly sampled in the upper respiratory tract by NP swab, most fatalities arise from involvement of the lower respiratory tract. As the risk of transmission is a function of viral load in exhaled droplets, there is a strong argument for assaying the viral load in exhaled breath. To assay the SARS-CoV-2 RNA in human breath, a hand-held breathalyzer that reverse-transcribed RNA to DNA at the site of sample collection was developed. Human breath can be readily precipitated from the interior surface of an inflated party balloon after a one-hour incubation at -20C. Importantly, rRNA can be readily detected by RT-PCR in this liquid without the need for RNA extraction ( Figure 1A ). While this collection technique is simple, it is unsuitable for a home diagnostic kit due to J o u r n a l P r e -p r o o f difficulties with standardization and performing RT chemistry on the balloon's surface. To overcome these limitations, the Bubbler was developed as an alternate capture device. The prototype used in the clinical study was a modified 15 mL Falcon tube with a glass straw which allows exhaled breath to be bubbled through an oil/RT mixture emulsion ( Figure 1B) . Initial studies demonstrated that Bubbler samples had a similar level of RT-PCR efficiency to RNA extracted from cultured cells as more rRNA could be detected from a single (<10 sec.) breath than could be detected from conventionally-extracted RNA (Figure 2A ).

In order to assess both the diagnostic potential of exhaled breath as well as the viability of performing reverse transcription at the site of sample collection, patients in the emergency department of Rhode Island Hospital were enrolled in a clinical study to test the Bubbler (Supplemental Table S2 ). Performing reverse transcription at the site of collection simplifies the protocol by eliminating the stabilization and RNA extraction steps. Kits were constructed to include one Bubbler and two saliva/tongue scrapes as controls. As exhaled breath could J o u r n a l P r e -p r o o f easily be contaminated with fluid from the oral cavity, several experiments were conducted to compare samples collected from the Bubbler to the control.

Interestingly, samples collected from the tongue scrape were positive for expression of the ACE2 receptor whereas ACE2 signal was undetectable in Bubbler samples, suggesting the Bubbler and tongue scrape sample RNA from distinct compartments ( Figure 2B ).

To determine if SARS-CoV-2 could be detected from the Bubbler, an RT-PCR assay to amplify SARS-CoV-2 RNA was optimized on a commercially available positive control. The optimization yielded RT and PCR primers that performed with similar sensitivity to the CDC primers, N1 and N2 (Supplemental Figure S1 ).

Amplification of the housekeeping gene RNase P was used as a sample control.

Reverse transcriptase reaction mixtures were added to Bubblers and tongue scrape tubes and packaged in test kits that were administered to consenting While comparing multiple assays of unknown error rate is limited by a lack of clearly defined true positives, the increased predictive power of the Bubbler for COVID-19 cases accompanied by evidence of lower respiratory track involvement (e.g. pneumonia visualized by X-ray) is reminiscent of compartmentalization of influenza. These results position the Bubbler as an attractive alternative to bronchoalveolar lavage for sampling the lower respiratory track.

An additional problem with benchmarking the Bubbler against NP swabs and tongue scrapes is the possibility that the PCRs performed on these samples are J o u r n a l P r e -p r o o f measuring the same amplicon in different contexts (e.g. genome in viral particle; viral transcripts in lysed cells, etc.). To better characterize the sample collected by the Bubbler, the composition of cellular RNAs in exhaled air collected from 70 patients was reanalyzed. RNase P levels were used as a proxy to compare the ratio of cellular to SARS-CoV-2 RNA in exhaled breath relative to conventionallycollected samples. RNase P is expected to be expressed in every cell whereas SARS-CoV-2 RNA is presumably localized to airborne viral particles and material released from lysed cells. The data suggests the Bubbler sample is more weighted towards viral particles as the ratio of Ct scores of SARS-CoV-2 to RNase P were over 3-fold higher than observed in the tongue scrape (Supplemental Table S1 ).

An advantage of performing reverse transcription in the collection tube was to use barcoded cDNA in a high throughput testing scheme ( Figure 4A ). Each RT primer targets a window of RNA but still functions with additional sequence at the 5' end. This sequence consisted of a T7 promoter (to amplify the signal), a 8-J o u r n a l P r e -p r o o f nucleotide sample barcode, and a 3-nucleotide random tag (to distinguish unique RT events from duplicates that arise in amplification). In order to test the detection limit of this assay, barcoded primers were used to test in triplicate a series of ten five-fold dilutions of SARS-CoV-2 as well as two water-based blanks.

Samples are reverse transcribed, pooled and then subjected to a two-step nested PCR strategy ( Figure 4B , 4C). After sequencing the resulting amplicons, barcodes were counted and associated with individual amplification events. Barcode counts were highly correlated across replicates and with the expected counts ( Figure 4D ). The correlation was lost at the 5 th serial dilution corresponding to a detection limit of 334 genomic copies. While robust in its current form, it is likely that this technique could be optimized further.

A primary concern for indoor facilities reopening after the COVID-19 pandemic is the safety of their airspace and the effectiveness of ventilation systems. To address this, the Bubbler was configured to sample environmental air instead of J o u r n a l P r e -p r o o f human breath. To model the movement of droplets exhaled in human breath, three uniquely sized synthetic oligonucleotides were put into three humidifiers at different locations in a room with high airflow ( Figure 5A ) and in another room with low air flow ( Figure 5C ). In general, the Bubbler was more biased by proximity to the source in the high ventilation setting relative to the poorly ventilated room. For example, when the Bubbler was placed 20 cm downstream of humidifier H1, PCR revealed exclusively H1 signal ( Figure 5B ). However, when the Bubbler was located 20 cm upstream of H1, all three point sources contributed weakly to the signal. In contrast, Bubbler samples from the low ventilation room showed less proximity bias ( Figure 5C ). While the closest humidifier was the dominant signal, oligonucleotides from all three humidifiers contributed to the signal over a much larger distance. While a detailed exploration of this application is beyond the scope of this text, it demonstrates the potential to use aerosolized nucleic acids to quantitatively map airflow in indoor spaces and also the potential to detect SARS-CoV-2 in the air. Table S2 ). As the data suggests that the Bubbler samples a compartment that is enriched in SARS-CoV-2, this sample collection method is likely to be a better indicator of current infection than NP swabs while still matching the hospital assay in predicting abnormal X-ray results.

The CDC recommends upper respiratory specimens for initial diagnostic testing for SARS-CoV-2 infection. Despite yielding the highest viral loads for the detection of SARS-CoV-2 9 , sample collection via sputum induction is not recommended due to the likelihood of aerosolization. Collection of lower respiratory tract samples from patients with suspected COVID-19 pneumonia is only recommended when an upper respiratory tract sample is negative (https://www.covid19treatmentguidelines.nih.gov, last accessed August 17, 2021). The most common testing for upper respiratory specimens has been the NP swab. However, NP swabs also carry an aerosolization risk as they are so uncomfortable that patients often cough, sneeze or gag during the procedure 10 .

One patient in our study even refused the conventional swab due to a prior J o u r n a l P r e -p r o o f negative experience (patient 21, Supplemental Table S2 ). Alternative assays such as the Bubbler estimate lower respiratory samples, with the safety of an upper respiratory sample. In addition, finding NP swab alternatives can relieve supply chains for the swabs and transport media, reduce the need for personal protective equipment during aerosolization and provide a more comfortable patient experience.

Finally, this work demonstrates how barcoding can enable high throughput RNA virus testing at a fraction of the cost of conventional testing. In addition to the cost saving and time saving from parallelization, the diagnosis-by-sequencing method enables strain identification which may prove useful as more information is learned about transmissibility and possible strain-specific treatment decisions.

While COVID-19 cases are currently declining, the need for mass testing is still strong, and this need could be exacerbated if a vaccine-resistant strain emerges.

During the 2019 COVID pandemic, testing was often limited for different reasons.

Initial problems with establishing a reliable diagnostic gave way to a lack of capacity at diagnostic labs and eventual shortages in reagents necessary to run diagnostic tests. Here, this study offers a tool that is orthogonal to existing protocols and better tolerated than swabs.

In addition to diagnostics, this study demonstrates how the Bubbler can be adapted for environmental sampling. Personal humidifiers were used as point sources of water droplets with unique nucleic acid signatures, and the Bubbler's relative capture rate of each source was measured. This technique provides a quantitative map of airflow in a room, and it can also be used to sample SARS-CoV-2 in circulating air. Such technology could be useful in restoring service to industries such as hotels, cruise ships and casinos as restrictions on indoor gatherings are relaxed. There is also an epidemiological benefit to routine testing of air at early warning sites such as hospital emergency rooms, potential transmission hubs (airplanes, bus and rail stations, schools) and buildings that house vulnerable populations (e.g. nursing homes, correction facilities, homeless J o u r n a l P r e -p r o o f 30 shelters). The addition of sequencing to these assays (as in Figure 4 ) adds the capacity to detect spikes in circulating viruses and monitor the spread of strains in a community. TCAGATTC, TATGCCAG,   TGGCTCAG, TCATTGAG, TGTATGCG,   TCCAGTCG, TACTTCGG, TGAACTGG,   TTGGTATG, TAACGCTG, TTCCATTG, TGTGGTTG,   TACAGGAT, TTCCTGCT, TGCGATCT, TGCATAGT,   TGATACGT, TCGAGCGT   18S TGGTTGTT, TGTACCTT, TCTGCTGT, TTGGAGGT,   TCGAGCGT, TGATACGT, TGCATAGT, TGCGATCT,   TTCCTGCT, TACAGGAT, TGTGGTTG, TTCCATTG,   TAACGCTG, TTGGTATG, TGAACTGG,   TACTTCGG, TCCAGTCG, TGTATGCG, TCATTGAG,   TGGCTCAG, TATGCCAG, TCAGATTC 

The size and the duration of air-carriage of respiratory droplets and droplet-nuclei

Aerosol emission and superemission during human speech increase with voice loudness

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study

Virological assessment of hospitalized patients with COVID-2019

Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community

Topographical continuity of bacterial populations in the healthy human respiratory tract

A: Lung epithelium-specific proteins: characteristics and potential applications as markers

Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing

SARS-CoV-2 N-RT1 5

SARS-CoV-2 N-RT2 5

SARS-CoV-2 N-RT3 5

SARS-CoV-2 N-RT4 5

SARS-CoV-2 N-RT6 5

SARS-CoV-2 N-RT7 5

SARS-CoV-2 N-RT8 5

SARS-CoV-2 N-qPCR-F1 5

SARS-CoV-2 N-qPCR-R1 5'-GCAAAGCAAGAGCAGCATCAC-3'

SARS-CoV-2 N-qPCR-F2 5'-GGTGTTAATTGGAACGCCTTGTCCTC-3'

SARS-CoV-2 N-qPCR-R2 5'-TCTTGGTTCACCGCTCTCACTCA-3'

J o u r n a l P r e -p r o o f